Iodine-Labeled Chemoembolization Microspheres for Controlled Tumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing chemoembolization and radioembolization treatments for tumors suffer from short embolization times, burst drug release, systemic toxicity, and radiation damage to non-tumor areas, limiting therapeutic efficacy and causing side effects.
Innovation Solution
A multifunctional microsphere preparation made of polyvinyl alcohol derivative and N-acryl amino acid monomer, capable of encapsulating chemotherapy drugs and labeling radionuclide iodine, providing stable embolization, slow drug release, and enabling real-time imaging through emission computed tomography or single photon emission computed tomography.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If lipiodol is used as embolization agent, then chemoembolization treatment can be performed, but embolization time is short and burst release of chemotherapeutic drugs occurs causing toxic reactions in normal tissues
Solution Approach 1:
The patent changes the physical state parameter of the embolization agent from liquid (lipiodol) to solid (microspheres with 50-200 μm diameter), which fundamentally alters the embolization mechanism from transient occlusion to permanent blockage, thereby extending embolization time and enabling controlled drug release
Solution Approach 2:
The patent creates a composite microsphere system comprising polyvinyl alcohol derivative skeleton, encapsulated chemotherapeutic drugs, and labeled radionuclide iodine. This composite structure integrates embolization, chemotherapy, and radiotherapy functions while controlling drug release kinetics to avoid burst release and reduce systemic toxicity
2Productivity
If 131I labeled lipiodol is used for internal irradiation radiotherapy, then therapeutic effect is achieved, but deposition in lung causes side effects such as lung injury
Solution Approach 1:
The patent changes the physical form of the radioembolization carrier from liquid lipiodol to solid microspheres, enabling precise control of particle size (50-200 μm) that matches tumor vasculature dimensions. This ensures selective embolization of tumor blood vessels while preventing pulmonary deposition, thereby maintaining radiotherapy efficacy while reducing lung injury
Solution Approach 2:
The patent achieves localized delivery of radionuclide iodine-131 to tumor sites through microsphere embolization. The microspheres with controlled size and surface properties selectively accumulate in tumor vasculature, concentrating the therapeutic radiation dose at the target site while minimizing exposure to normal lung tissue
3Productivity
If external irradiation is combined with chemoembolization, then survival time is prolonged, but radiation damage to non-tumor areas causes great side effects
Solution Approach 1:
The patent extracts the radiation source from external beam radiotherapy and incorporates it directly into the embolization microspheres via radionuclide iodine-131 labeling. This transforms external irradiation into internal irradiation, where the radioactive source is delivered directly to the tumor site through the embolized blood vessels, eliminating radiation exposure to non-tumor areas while maintaining therapeutic efficacy
Solution Approach 2:
The patent merges embolization therapy, chemotherapy, and internal radiotherapy into a single integrated microsphere preparation. The microspheres simultaneously provide mechanical embolization, encapsulated chemotherapeutic drugs, and labeled radionuclide iodine-131 for internal irradiation, achieving synergistic therapeutic effect while reducing the need for external irradiation and its associated side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microspheres achieve synergistic tumor treatment with reduced drug and nuclide doses, enhancing therapeutic effect while minimizing side effects and allowing precise monitoring, with a median survival time improvement in treated rats.
Implementation Method 1
Therapeutic radionuclide 131I has a decay half-life of 8 days and emits β ray. The maximum energy of the β ray is 0.81 MeV. The maximum penetration depth is 2 mm, which is an ideal internal irradiation nuclide.
Implementation Method 2
It also emits γ ray. The maximum energy of ray is 364 keV, which can be used for emission computed tomography imaging or single photon emission computed tomography imaging.
Implementation Method 3
design and prepare new microsphere preparations to achieve stable labeling of radionuclide iodine
Implementation Method 4
stable encapsulation of chemotherapy drugs, and permanent embolization of tumor blood vessels
Data Source
AI summary
In the microsphere preparation for chemoembolization therapy and nuclear medicine imaging of tumor, and a preparation method thereof, the microsphere is formed by means of using a polyvinyl alcohol derivative as a framework material and polymerizing, crosslinking and curing same with an N-acryl amino acid monomer. The microsphere can label radionuclide iodine and can also absorb load chemotherapeutic drugs.